Aspartic Acid Endopeptidases
"Aspartic Acid Endopeptidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sub-subclass of endopeptidases that depend on an ASPARTIC ACID residue for their activity.
| Descriptor ID |
D016282
|
| MeSH Number(s) |
D08.811.277.656.074.500 D08.811.277.656.300.048
|
| Concept/Terms |
Aspartic Acid Endopeptidases- Aspartic Acid Endopeptidases
- Acid Endopeptidases, Aspartic
- Endopeptidases, Aspartic Acid
- Aspartyl Endopeptidases
- Endopeptidases, Aspartyl
- Aspartic Endopeptidases
|
Below are MeSH descriptors whose meaning is more general than "Aspartic Acid Endopeptidases".
Below are MeSH descriptors whose meaning is more specific than "Aspartic Acid Endopeptidases".
This graph shows the total number of publications written about "Aspartic Acid Endopeptidases" by people in this website by year, and whether "Aspartic Acid Endopeptidases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 1 | 3 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 2 | 5 |
| 2003 | 1 | 3 | 4 |
| 2004 | 0 | 4 | 4 |
| 2006 | 2 | 1 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aspartic Acid Endopeptidases" by people in Profiles.
-
The human pathobiont Malassezia furfur secreted protease Mfsap1 regulates cell dispersal and exacerbates skin inflammation. Proc Natl Acad Sci U S A. 2022 12 06; 119(49):e2212533119.
-
Control of ?-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-?/? and Nuclear Factor ?-B. Curr Alzheimer Res. 2021; 18(12):941-955.
-
Rivastigmine modifies the a-secretase pathway and potentially early Alzheimer's disease. Transl Psychiatry. 2020 02 03; 10(1):47.
-
Evidence of a novel mechanism for partial ?-secretase inhibition induced paradoxical increase in secreted amyloid ? protein. PLoS One. 2014; 9(3):e91531.
-
Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
-
Metabolic stress modulates Alzheimer's ?-secretase gene transcription via SIRT1-PPAR?-PGC-1 in neurons. Cell Metab. 2013 May 07; 17(5):685-94.
-
Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces ?-secretase (BACE1) levels and A? generation. J Biol Chem. 2012 Mar 09; 287(11):8424-33.
-
Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
-
The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
-
AT-1 is the ER membrane acetyl-CoA transporter and is essential for cell viability. J Cell Sci. 2010 Oct 01; 123(Pt 19):3378-88.